Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Rajasthan Royals launch ANOTHER bid to invest in cash
Tibet kicks off culture, tourism expo
Coachella food prices SHOCK fans as festival
China's Dunhuang, French museum to co
Dallas TikTok star Camryn Herriage speaks for the first time after hit
Content broadcasting network exhibition to open in Beijing
Pressure mounts on CBA to halt hoops slump
China sanctions former US lawmaker who supported Taiwan
Tardy claims maiden LPGA title at Blue Bay in China
Election deniers moving closer to GOP mainstream as Trump allies fill Congress, report shows
Aroma of Chinese Lamian noodles wafts to Belt and Road countries